Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
Public ClinicalTrials.gov record NCT01390220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects With Seizure Clusters. ARTEMIS-1: Acute Rescue Therapy in Epilepsy With Midazolam Intranasal Spray-1
Study identification
- NCT ID
- NCT01390220
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Enrollment
- 292 participants
Conditions and interventions
Conditions
Interventions
- USL261 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2011
- Primary completion
- Feb 28, 2017
- Completion
- Feb 28, 2017
- Last update posted
- Oct 9, 2019
2011 – 2017
United States locations
- U.S. sites
- 46
- U.S. states
- 27
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| United States, Arizona | Phoenix | Arizona | — | — |
| United States, Arizona | Tucson | Arizona | — | — |
| United States, Arkansas | Little Rock | Arkansas | — | — |
| United States, California | Fresno | California | — | — |
| United States, California | Irvine | California | — | — |
| United States, California | Loma Linda | California | — | — |
| United States, California | Sacramento | California | — | — |
| United States, California | Ventura | California | — | — |
| United States, Colorado | Aurora | Colorado | — | — |
| United States, Connecticut | New Haven | Connecticut | — | — |
| United States, Florida | Gainesville | Florida | — | — |
| United States, Florida | Gulf Breeze | Florida | — | — |
| United States, Florida | Port Charlotte | Florida | — | — |
| United States, Florida | Tampa | Florida | — | — |
| United States, Florida | Wellington | Florida | — | — |
| United States, Idaho | Boise | Idaho | — | — |
| United States, Illinois | Chicago | Illinois | — | — |
| United States, Kansas | Manhattan | Kansas | — | — |
| United States, Kentucky | Lexington | Kentucky | — | — |
| United States, Maryland | Baltimore | Maryland | — | — |
| United States, Michigan | Detroit | Michigan | — | — |
| United States, Minnesota | Saint Paul | Minnesota | — | — |
| United States, Missouri | Chesterfield | Missouri | — | — |
| United States, Missouri | St Louis | Missouri | — | — |
| United States, Nevada | Reno | Nevada | — | — |
| United States, New Hampshire | Lebanon | New Hampshire | — | — |
| United States, New Jersey | Flemington | New Jersey | — | — |
| United States, New Jersey | Hackensack | New Jersey | — | — |
| United States, New York | New York | New York | — | — |
| United States, New York | Stony Brook | New York | — | — |
| United States, New York | The Bronx | New York | — | — |
| United States, North Carolina | Durham | North Carolina | — | — |
| United States, North Carolina | Winston-Salem | North Carolina | — | — |
| United States, Ohio | Columbus | Ohio | — | — |
| United States, Oklahoma | Oklahoma City | Oklahoma | — | — |
| United States, Oregon | Portland | Oregon | — | — |
| United States, Pennsylvania | Philadelphia | Pennsylvania | — | — |
| United States, Tennessee | Memphis | Tennessee | — | — |
| United States, Tennessee | Nashville | Tennessee | — | — |
| United States, Texas | Dallas | Texas | — | — |
| United States, Texas | Fort Worth | Texas | — | — |
| United States, Texas | Greenville | Texas | — | — |
| United States, Texas | San Antonio | Texas | — | — |
| United States, Texas | Temple | Texas | — | — |
| United States, Virginia | Norfolk | Virginia | — | — |
| United States, Wisconsin | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01390220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01390220 live on ClinicalTrials.gov.